Island Pharma hires ex-BioCryst leader to accelerate Galidesivir biodefence push
Island Pharmaceuticals has appointed Raymond Taylor, formerly of BioCryst Pharmaceuticals, as Senior Scientific Fellow to advance its antiviral drug, Galidesivir, for Marburg Virus Disease. Taylor's extensive experience and track record in securing biodefence funding are expected to bolster Island's efforts to gain U.S. government support and procurement opportunities for the drug. This strategic hire aims to accelerate Galidesivir's development through the U.S. FDA's Animal Rule pathway, reinforcing Island's position in the global biodefence market.
BioCryst director Amy McKee sells $100,284 in company shares
Amy E. McKee, a director at BioCryst Pharmaceuticals Inc. (BCRX), sold 11,180 shares of the company’s common stock for $100,284, at an average price of $8.97 per share. This sale comes as the company's shares have risen 29% over the past six months. BioCryst Pharmaceuticals also recently reported a significant Q1 2026 EPS miss but exceeded revenue expectations.
Insider Selling: Amy Mckee Sells 11,180 Shares of BioCryst Pharm
Amy Mckee, a Director at BioCryst Pharmaceuticals Inc (BCRX), sold 11,180 shares of the company on May 18, 2026. This transaction leaves her with 31,252 shares. BioCryst Pharmaceuticals shows a history of 9 insider sells and no buys over the past year, and the stock is currently considered a "Possible Value Trap" based on its GF Value.
Director at Biocryst (NASDAQ: BCRX) sells 11,180 shares at $8.97
Amy E. McKee, a director at BIOCRYST PHARMACEUTICALS INC (NASDAQ: BCRX), sold 11,180 shares of common stock in an open-market transaction at a weighted average price of $8.97 per share. The individual transaction prices ranged from $8.96 to $8.985. Following this sale, McKee directly holds 31,252 shares of the company's stock.
BCRX (NASDAQ) Form 144: Affiliate plans resale of 11,180 shares
BioCryst Pharmaceuticals Inc. (BCRX) has filed a Form 144, indicating an affiliate's intent to sell 11,180 shares of common stock. This filing details two stock-plan related dispositions, with shares acquired on June 7, 2023 (4,360 shares) and June 12, 2025 (6,820 shares), facilitated by Merrill Lynch. As of May 18, 2026, 254,162,660 shares of BCRX are outstanding.
BioCryst Pharmaceuticals’ SWOT analysis: stock eyes growth beyond single product
BioCryst Pharmaceuticals (NASDAQ:BCRX) is transitioning from a single-product company to a diversified rare disease specialist, driven by the pediatric approval of Orladeyo and a promising pipeline candidate. The company achieved strong financial results in 2025, with projections for non-GAAP profitability in 2026, and faces both significant growth opportunities, particularly in the pediatric HAE market, and challenges related to its reliance on Orladeyo and pipeline execution risks. Analysts maintain a "strong buy" consensus, with an average price target suggesting substantial upside potential.
BioCryst Pharmaceuticals’ SWOT analysis: stock gains ground on pediatric approval
BioCryst Pharmaceuticals is seeing strengthened prospects in 2026 due to FDA approval of Orladeyo for pediatric hereditary angioedema, opening a significant new market. The company reported strong Q4 2025 Orladeyo sales and provided optimistic 2026 sales guidance, aiming for non-GAAP profitability. While Orladeyo's success drives current growth, the company faces concentration risk and is developing a pipeline drug for Netherton syndrome, BCX17725, to diversify its revenue streams.
BioCryst Pharmaceuticals’ SWOT analysis: stock eyes growth path
BioCryst Pharmaceuticals (NASDAQ:BCRX) is transitioning into a profitable commercial enterprise, driven by its lead product Orladeyo, which recently received FDA approval for pediatric use, expanding its market. Analysts project a 27% upside potential for the stock, with the company aiming for non-GAAP profitability in 2026 and long-term revenue targets of over $1.8 billion by 2033, supported by pipeline development and strategic acquisitions. Despite reliance on Orladeyo, the company is poised for growth through market expansion, disciplined cost management, and promising new therapies.
European Navenibart Deal And Reaffirmed 2026 Outlook Could Be A Game Changer For BioCryst (BCRX)
BioCryst Pharmaceuticals (BCRX) reported Q1 revenue of US$156.41 million and a net loss of US$721.81 million, yet maintained its full-year 2026 revenue guidance. A new European licensing deal for navenibart, including a US$70 million upfront payment, is expected to provide immediate capital and streamline European operations. This deal, coupled with reaffirmed guidance, aims to reshape BioCryst's investment narrative by addressing near-term funding and focus, despite ongoing balance sheet risks.
BioCryst Pharmaceuticals, Inc. $BCRX Shares Bought by VIRGINIA RETIREMENT SYSTEMS ET Al
Virginia Retirement Systems ET Al significantly increased its stake in BioCryst Pharmaceuticals (BCRX) by 106.5% in the fourth quarter, with other institutional investors also adding shares, bringing institutional ownership to 85.88%. Despite a consensus "Moderate Buy" rating and an average price target of $20.70 from analysts, the company's stock fell 5.7% after reporting a substantial quarterly EPS loss of $2.98, although revenue slightly exceeded expectations. Insider transactions also showed a sale of 150,000 shares by an insider.
BioCryst’s Navenibart Deal And Pediatric Data Shape HAE Investment Case
BioCryst Pharmaceuticals has licensed European rights for navenibart, a hereditary angioedema (HAE) treatment, to Neopharmed Gentili, and presented new pediatric HAE data. These developments, including an upfront payment and potential milestones, focus on strengthening BioCryst's position in the HAE market and addressing a critical unmet need for patients. The company's stock is currently trading significantly below analyst price targets and Simply Wall St's fair value estimation.
Biocryst (BCRX) CLO sells 62,500 shares in pre-set 10b5-1 trade
Alane P. Barnes, Chief Legal Officer of Biocryst Pharmaceuticals Inc. (BCRX), exercised employee stock options for 62,500 shares at $5.04 per share and simultaneously sold an equal number of shares at $9.54 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating it was automatic and not a discretionary trade. Following the sale, Barnes directly retains 400,703 shares of Biocryst common stock.
BioCryst’s Navenibart Deal And Pediatric Data Shape HAE Investment Case
BioCryst Pharmaceuticals has licensed exclusive European rights for navenibart, its hereditary angioedema (HAE) treatment, to Neopharmed Gentili, including upfront and potential milestone payments. Concurrently, BioCryst presented real-world pediatric HAE data, highlighting ongoing patient burdens. Both developments aim to strengthen BioCryst's focus on HAE and impact future treatment adoption, while the company's financial structure and balance sheet strength remain key considerations for investors.
BioCryst Pharmaceuticals stock (US09058V1035): Shares surge 9% after earnings
BioCryst Pharmaceuticals (BCRX) shares surged 9.09% to $9.60 on May 13, 2026, driven by a Q1 revenue increase of 7.5%, despite missing EPS estimates. Analysts maintain a "Moderate Buy" rating with a target price of $20.70, reflecting significant upside potential. The company's focus on innovative oral small-molecule therapies for rare diseases, particularly its HAE treatment ORLADEYO, positions it well in the growing biotech sector.
62,500-share resale registered by BCRX insider (NASDAQ: BCRX)
A Form 144 filing indicates that a BCRX insider has registered to resell 62,500 shares of common stock, stemming from an option granted in 2017. The sale, valued at $596,250.00, is slated for May 13, 2026, and follows a prior sale of 150,000 shares on March 16, 2026, for over $1.3 million. This registration is described as a routine compliance procedure for insider trading.
BCRX Jumps As Price Target Hike Caps Busy Catalyst Week
BioCryst Pharmaceuticals (BCRX) stock is trading up after Citizens boosted its price target to $28 and reaffirmed an Outperform rating, citing strong Orladeyo demand and pipeline upside. The company also secured a European navenibart deal worth up to $345M and reaffirmed its 2026 revenue guidance, despite a Q1 GAAP loss due to a one-time charge. This combination of analyst confidence, strategic partnerships, and steady business performance, alongside favorable chart action, is drawing significant attention from momentum traders.
BioCryst to Present New Real-World Evidence Underscoring
BioCryst Pharmaceuticals will present new real-world evidence at the 2026 ISPOR conference, highlighting the significant burden of hereditary angioedema (HAE) in pediatric patients and their caregivers. The research, based on U.S. insurance claims data and caregiver insights, demonstrates greater healthcare resource utilization (HCRU) and significant impacts on caregivers' quality of life for children with HAE. These findings underscore the persistent unmet needs and the importance of optimized disease management in this patient population.
BioCryst Pharmaceuticals to Present Data on Challenges Faced by Pediatric HAE Patients at ISPOR 2026
BioCryst Pharmaceuticals is set to present new real-world evidence at the ISPOR 2026 conference, highlighting the persistent challenges faced by children with hereditary angioedema (HAE). The presentation will underscore the significant burden this condition places on young patients, offering insights into the specific difficulties and impact on their lives. This data aims to shed light on the realities of living with HAE for the pediatric population.
Study: Kids with rare swelling disorder log 3x outpatient visits vs peers
BioCryst will present new real-world evidence at ISPOR 2026 detailing the significant burden of pediatric hereditary angioedema (HAE) on both young patients and their caregivers. Studies show that children with HAE have over three times more outpatient visits than their peers and that caregivers spend more than 20 hours weekly providing care, indicating persistent unmet needs in disease management. These findings aim to support the positioning of current and future therapies for pediatric HAE and highlight the impact on quality of life.
BioCryst to Present New Real-World Evidence Underscoring
BioCryst Pharmaceuticals will present new real-world evidence at the ISPOR 2026 conference, highlighting the significant burden of hereditary angioedema (HAE) in pediatric patients and their caregivers. Two studies will be presented: one analyzing healthcare resource utilization in pediatric HAE patients using insurance claims data, and another exploring the quality-of-life impact on caregivers. The research emphasizes the unmet needs and the importance of optimized disease management to improve outcomes for children with HAE.
Earnings call transcript: BioCryst Pharmaceuticals Q1 2026 misses EPS, revenue up
BioCryst Pharmaceuticals reported mixed Q1 2026 results, with a significant EPS miss (-2.98 vs. 0.05 forecast) but exceeding revenue expectations at $156.41 million. The revenue beat was primarily driven by strong ORLADEYO sales, though the company faces a manufacturing delay for ORLADEYO pediatric pellets. BioCryst maintains a strong liquidity position and expresses confidence in its product pipeline, including navenibart and BCX17725, with an optimistic outlook for long-term growth and strategic initiatives.
State Street (NASDAQ: BCRX) holds 4.9% of BioCryst, 12.2M shares
State Street Corporation has reported a 4.9% beneficial ownership in BioCryst Pharmaceuticals (NASDAQ: BCRX), holding 12,208,360 shares as of March 31, 2026. This ownership includes shared voting power for 11,618,245 shares and shared dispositive power for all 12,208,360 shares. The filing, a Schedule 13G, indicates a passive investment below the 5% threshold, with ownership largely managed through custodial and asset-manager arrangements.
Influenza Therapeutics Market to Reach USD 12.94 Billion by 2033
The global Influenza Therapeutics Market is projected to reach USD 12.94 billion by 2033, growing at a CAGR of 4.1% from an estimated USD 9.36 billion in 2025. This growth is driven by the increasing incidence of seasonal influenza, rising demand for antiviral drugs and vaccines, and growing healthcare expenditure. North America currently holds the largest market share at 38%, with key players like F. Hoffmann-La Roche, Teva Pharmaceuticals, and BioCryst Pharmaceuticals leading innovations in the sector.
Biocryst strikes $300M deal for HAE drug navenibart in Europe
Biocryst Pharmaceuticals has partnered with Neopharmed Gentili, specifically its Irish affiliate, for the European marketing rights to navenibart, an experimental drug for hereditary angioedema (HAE). The deal could be worth over $300 million to Biocryst, including an upfront payment of $70 million. Navenibart is currently in Phase 3 clinical trials and is designed to prevent HAE attacks by blocking kallikrein.
Is BioCryst Pharmaceuticals (BCRX) Pricing Reflect Its Pipeline Progress And Recent Share Performance Changes
BioCryst Pharmaceuticals (BCRX) stock, despite recent fluctuations, is considered significantly undervalued according to a Discounted Cash Flow (DCF) analysis, which estimates its intrinsic value at $74.62 per share against a current price of $8.90. The company also trades below both its industry average and its tailored Fair Ratio based on a Price-to-Sales (P/S) comparison, further suggesting it is undervalued. The article highlights the importance of pipeline progress and market sentiment in the biotech sector, suggesting investors use "Narratives" to align financial forecasts with their investment views.
H.C. Wainwright Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $32
H.C. Wainwright has reiterated its Buy rating on BioCryst Pharmaceuticals (BCRX.US) and maintained its target price of $32. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2026 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (BCRX) reported its Q1 2026 earnings, with ORLADEYO net revenue of $148.3 million, aligning with expectations. The company is actively progressing its pipeline, including the navenibart ALPHA-ORBIT trial and the BCX17725 Phase 1 study for Netherton syndrome, and has finalized a licensing agreement for navenibart in Europe. Despite a manufacturing issue delaying the pediatric ORLADEYO launch, the company maintains its full-year revenue guidance, emphasizing strong operational results and a solid financial position.
BioCryst (NASDAQ: BCRX) grows ORLADEYO sales and reaffirms 2026 outlook
BioCryst Pharmaceuticals reported strong Q1 2026 ORLADEYO sales of $148.3 million, up 11% year-over-year, contributing to a total revenue of $156.4 million. Despite a GAAP operating loss of $701.6 million due to a non-cash acquired in-process R&D charge from the Astria Therapeutics acquisition, the company posted a non-GAAP operating profit of $54.2 million. BioCryst reaffirmed its 2026 financial guidance for ORLADEYO net revenue between $625–$645 million and total revenue between $635–$660 million, following a licensing agreement for navenibart in Europe worth up to $275 million in milestones.
BioCryst Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
BioCryst Pharmaceuticals Inc has released its earnings summary for the quarter that concluded on March 31. The report, provided by Refinitiv, offers a brief overview of the company's financial performance. Further details would typically be found in the full earnings report.
BioCryst Pharmaceuticals (BCRX) Quarterly Loss Of US$721.8m Challenges Bullish Earnings Narratives
BioCryst Pharmaceuticals reported a significant Q1 2026 loss of US$721.8 million, a sharp reversal from a profit in Q4 2025, despite a slight increase in trailing 12-month revenue. This quarterly loss, coupled with negative shareholders' equity and high debt, presents a challenge to optimistic analyst forecasts and highlights potential volatility and financial risks. While some investors see the stock as undervalued based on its P/E ratio and ORLADEYO's performance, skeptics point to earnings instability and reliance on a single drug.
Earnings Flash (BCRX) BioCryst Pharmaceuticals, Inc. Reports Q1 Revenue $156.4M, Vs. FactSet Est of $151.1M
BioCryst Pharmaceuticals, Inc. (BCRX) announced its Q1 revenue reached $156.4 million, surpassing the FactSet consensus estimate of $151.1 million. This report highlights the company's financial performance for the first quarter.
BioCryst (NASDAQ: BCRX) takes $697.8M navenibart R&D hit after Astria deal
BioCryst Pharmaceuticals reported a significant net loss of $721.8 million for Q1 2026, primarily due to a substantial $697.8 million R&D expense related to the acquisition of Astria Therapeutics and its lead product candidate, navenibart. Despite this one-time charge, the company saw an increase in total revenues to $156.4 million, largely driven by strong ORLADEYO sales. BioCryst also secured a new $400 million term loan from Blackstone to help finance the Astria deal and recently entered a European licensing agreement for navenibart with Neopharmed Gentili.
BioCryst Pharmaceuticals 1Q Loss/Shr $2.98 >BCRX
BioCryst Pharmaceuticals reported a first-quarter loss per share of $2.98. This financial update is identified with the stock symbol BCRX.
BioCryst Pharmaceuticals Q1 2026 earnings preview
This article provides a Q1 2026 earnings preview for BioCryst Pharmaceuticals. It anticipates upcoming financial results for the company.
BIOCRYST PHARMACEUTICALS ($BCRX) Releases Q1 2026 Earnings
BIOCRYST PHARMACEUTICALS ($BCRX) reported its Q1 2026 earnings, missing EPS estimates but exceeding revenue expectations. The company posted earnings of -$0.03 per share against an estimated $0.05, and revenue of $156.41 million, which beat the estimated $154.15 million. The article also details recent insider trading, institutional investor activity, government contracts received, congressional stock trading, and analyst ratings for BCRX.
White & Case advises Neopharmed Gentili on acquisition of exclusive rights to Navenibart in Europe from BioCryst Pharmaceuticals
White & Case LLP advised Neopharmed Gentili on a licensing agreement with BioCryst Pharmaceuticals for the European commercialization of navenibart, a treatment for hereditary angioedema (HAE). BioCryst will receive an upfront payment of US$70 million, up to US$275 million in regulatory and sales milestones, and tiered royalties. This acquisition further strengthens Neopharmed Gentili's rare disease portfolio.
Earnings Flash (BCRX) BioCryst Pharmaceuticals, Inc. Reports Q1 Revenue $156.4M, vs. FactSet Est of $151.1M
BioCryst Pharmaceuticals, Inc. reported Q1 revenue of $156.4 million, exceeding the FactSet estimate of $151.1 million. The company's stock symbol is BCRX, and the news was published on May 6, 2026, at 08:06 am EDT. This financial update indicates a stronger-than-expected revenue performance for BioCryst in the first quarter.
BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update
BioCryst Pharmaceuticals reported strong first-quarter 2026 financial results, with ORLADEYO net revenue reaching $148.3 million, an 11% year-over-year increase. The company also announced a licensing agreement for navenibart in Europe, valued at $70 million upfront and up to $275 million in milestone payments. BioCryst maintained its full-year 2026 revenue guidance for ORLADEYO and total revenue, while progressing its pipeline programs like ALPHA-ORBIT for navenibart and BCX17725 for Netherton syndrome.
BioCryst Pharmaceuticals earnings loom amid HAE market battle
BioCryst Pharmaceuticals is set to release its first-quarter earnings, with analysts expecting $0.05 earnings per share on $151.7 million in revenue. Investors will focus on the performance of its HAE drug, ORLADEYO, amid increasing competition and seasonal pressures. The company's pipeline candidate, navenibart, and its path to sustained profitability are also key areas of interest.
BioCryst: Q1 Earnings Snapshot
BioCryst Pharmaceuticals Inc. reported a first-quarter loss of $721.8 million, or $2.98 per share, which missed Wall Street expectations. Despite the loss, the drugmaker posted revenues of $156.4 million and anticipates full-year revenue between $635 million and $660 million. BioCryst shares have seen a 16% increase since the start of the year but are down 18% over the last 12 months.
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals, Inc. announced that its compensation committee granted restricted stock units (RSUs) covering 61,750 shares to six newly-hired employees. These grants, made as inducements for employment on May 1, 2026, align with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in four equal annual installments, contingent on continued service with the company.
BioCryst Pharmaceuticals earnings loom amid HAE market battle
BioCryst Pharmaceuticals is set to report its first-quarter earnings, with analysts focusing on the performance of its hereditary angioedema (HAE) drug, ORLADEYO, amid increasing market competition. The company's long-term prospects remain strong, with all analysts rating it a "Strong Buy," but investors will be looking for updates on its pipeline candidate navenibart and its path to sustained profitability. New approvals in the HAE market mean BioCryst must defend ORLADEYO's position against competitors offering convenience advantages.
Does BioCryst’s European Navenibart Licensing Deal and Cash Infusion Change The Bull Case For BCRX?
BioCryst Pharmaceuticals secured a European licensing deal for its investigational HAE therapy, navenibart, with an Irish affiliate of Neopharmed Gentili. The agreement includes a US$70 million upfront payment, potential milestones up to US$275 million, and tiered royalties, providing a capital infusion for BioCryst's Phase 3 development. While this deal strengthens short-term funding and leverages an existing European infrastructure, the company's long-term success still hinges on ORLADEYO's performance and navenibart's trial outcomes amidst rising competition in the HAE market.
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals, Inc. announced that its compensation committee granted restricted stock units (RSUs) covering 61,750 shares to six newly-hired employees. These RSUs were granted as inducements for employment, in accordance with Nasdaq Listing Rule 5635(c)(4), and will vest in four equal annual installments starting one year from the May 1, 2026 grant date.
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals, Inc. announced that its compensation committee granted restricted stock units (RSUs) covering 61,750 shares to six new employees. These grants, made on May 1, 2026, serve as inducements for their employment and comply with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in four equal annual installments, contingent on continued service with the company.
BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema
BioCryst Pharmaceuticals, Inc. has announced a licensing agreement with an Irish affiliate of Neopharmed Gentili for the commercialization of navenibart in hereditary angioedema (HAE) in Europe. BioCryst will receive an upfront payment of $70 million, with potential for up to $275 million in future milestone payments and royalties on sales ranging from 18% to 30%. This agreement builds on an existing partnership between the two companies and aims to optimize commercial focus while strengthening BioCryst's financial position, as the Phase 3 program for navenibart in HAE remains on track for a U.S. regulatory filing by the end of 2027.
BioCryst Pharmaceuticals announced that it has signed a licensing agreement with the Irish subsidiary of Neopharmed Gentili regarding the rights to the hereditary angioedema treatment drug Navenibart in Europe.
BioCryst Pharmaceuticals has entered into a licensing agreement with Neopharmed Gentili's Irish subsidiary for the European rights to Navenibart, a hereditary angioedema treatment. This collaboration aims to expand the global market presence of BioCryst's key product. The article highlights this as a significant step for BioCryst.
BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema
BioCryst Pharmaceuticals has partnered with an Irish affiliate of Neopharmed Gentili, granting exclusive rights to commercialize navenibart for hereditary angioedema (HAE) in Europe. The agreement includes an upfront payment of $70 million, up to $275 million in future milestone payments, and tiered royalties. This collaboration leverages an existing relationship, strengthens BioCryst's financial position, and aims to optimize commercial focus for the investigational drug.
BioCryst (NASDAQ: BCRX) licenses navenibart in Europe for $70M upfront
BioCryst Pharmaceuticals has signed a European licensing agreement with an Irish affiliate of Neopharmed Gentili for navenibart, an investigational treatment for hereditary angioedema. BioCryst will receive an upfront payment of $70 million, with potential for an additional $275 million in regulatory and sales milestone payments, plus tiered royalties ranging from 18% to 30% on net sales. This deal strengthens BioCryst’s financial position and leverages Neopharmed Gentili’s existing rare disease infrastructure in Europe, with navenibart's Phase 3 program still on track for a US regulatory filing by late 2027.
BioCryst lands $70M now, up to $275M more in Europe HAE deal
BioCryst Pharmaceuticals has granted an Irish affiliate of Neopharmed Gentili an exclusive license to commercialize navenibart for hereditary angioedema (HAE) in Europe. The deal includes an upfront payment of $70 million, with potential for up to $275 million in regulatory and sales milestones, plus tiered royalties of 18%-30%. This agreement builds on their previous partnership for ORLADEYO and aims to strengthen BioCryst's financial position while accelerating navenibart's path to market in Europe.
